Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are hiv-positive and treatment-naïve

Pharmacotherapy

Volumn 33, Issue 3, 2013, Pages 284-294

  Bertz, Richard J ^a   Persson, Anna ^a   Chung, Ellen ^a   Zhu, Li ^a   Zhang, Jenny ^a   McGrath, Donnie ^a   Grasela, Dennis ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiretroviral; Atazanavir; HAART; HIV; Pharmacodynamics; Pharmacokinetics; Ritonavir

Indexed keywords

ATAZANAVIR; LAMIVUDINE; RITONAVIR; STAVUDINE; VIRUS RNA;

ADULT; AGED; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; EYE JAUNDICE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 84875423255     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1205     Document Type: Article

References (31)

1. Perez-Elias MJ. Atazanavir: simplicity and convenience in different scenarios. Expert Opin Pharmacother 2007;8:689- 700.
2. Swainston HT, Scott LJ. Atazanavir: a review of its use in the management of HIV infection. Drugs 2005;65:2309-36.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. April 30, 2012. Department of Health and Human Services. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 30, 2012.
4. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300: 555-70.
5. Bristol-Meyers Squibb. Reyataz (atazanavir). US prescribing information. Princeton, NJ; 2012.
6. Ghosn J, Carosi G, Moreno S, et al. Unboosted atazanavirbased therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther 2010;15:993-1002.
7. Squires KE, Young B, DeJesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir.lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazavir in HIVinfected patients. AIDS 2010;24:2019-202.
8. Agarwala S, Russo R, Mummaneni V, Randall D, Geraldes M, O'Mara E. Steady-state pharmacokinetic interaction study of atazanavir with ritonavir in healthy subjects [Abstract H- 1716]. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, September 27-30, 2002.
9. Agarwala S, Eley T, Filoramo D, et al. Steady-state pharmacokinetics and inhibitory quotient of atazanavir with and without ritonavir in treatment naive HIV-infected patients [Abstract 85]. Presented at: 7th International Workshop of Clinical Pharmacology of HIV Therapy. Lisbon, Portugal, April 20-22, 2006.
10. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008;47:161-7.
11. Malan DR, Krantz E, David N, et al. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) 2010;9:34-42.
12. Shen L, Rabi SA, Siliciano RF. A novel method for determining the inhibitory potential of anti-HIV drugs. Trends Pharmacol Sci 2009;30:610-6.
13. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials 2004;5:201-5.
14. Bertz R, Li J, King M, et al. Lopinavir inhibitory quotient (IQ) predicts virological response in highly-antiretroviral (ARV) -experienced patients receiving high-dose lopinavir/ritonavir [Abstract 134]. Presented at: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
15. Gianotti N, Galli L, Danise A, et al. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. J Med Virol 2006;78:1537-41.
16. Hoefnagel JG, Koopmans PP, Burger DM, Schuurman R, Galama JM. Role of the inhibitory quotient in HIV therapy. Antivir Ther 2005;10:879-92.
17. Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004;43:845-53.
18. Marcelin AG, Flandre P, Peytavin G, Calvez V. Predictors of virologic response to ritonavir-boosted protease inhibitors. AIDS Rev 2005;7:225-32.
19. Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother 2005;56:380-7.
20. Winston A, Hales G, Amin J, van Schaick E, Cooper DA, Emery S. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment- experienced HIV-1-infected individuals. AIDS 2005;19: 1393-9.
21. Winston A, Patel N, Back D, et al. Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response. J Acquir Immune Defic Syndr 2006;41:675-6.
22. Levy AR, McCandless L, Harrigan PR, et al. Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis 2005;4:4.
23. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685- 94.
24. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368:476-82.
25. Vincent I, Piketty C, Gerard L, et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV-infected patients with multiple treatment failures: a substudy of puzzle2-ANRS 107 trial [Abstract 62]. 4th International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, 2003.
26. Zhu L, Laio S, Child M, et al. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir 300/100 mg once daily compared to lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed dose tenofovir- emtricitabine once daily, are supportive of 48 week efficacy and safety in HIV-1 infected, treatment-naive subjects [Abstract O23]. 9th International Workshop on Clinical Pharmacology of HIV Therapy, 2008.
27. Zeigler-Johnson CM, Walker AH, Mancke B, et al. Ethnic Differences in the Frequency of Prostate Cancer Susceptibility Alleles at SRD5A2 and CYP3A4. Hum Hered 2002;54:13- 21.
28. Anderson PL, Aquilante CL, Gardner EM, et al. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother 2009;64 (5):1071-9.
29. Castillo-Mancilla J, Aquilante C, Campbell T, et al. Effect of CYP3A5 polymorphisms on the metabolism of atazanavir in HIV-infected patients: a sub-study of AIDS Clinical Trials Group A5175 [abstract no. P-22]. 13th International Workshop of Clinical Pharmacology of HIV Therapy. Barcelona, Spain, April 2012.
30. Feldt T, Oette M, Kroidl A, et al. Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety. Eur J Med Res 2005;10:7-10.
31. Gianotti N, Seminari E, Guffanti M, et al. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. New Microbiol 2005;28:119-25.